Intra-arterial Cetuximab for Glioma
Phase-Based Progress Estimates
Effectiveness
Safety
Glioma+10 More
Intra-arterial Cetuximab - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial is testing a new way to treat brain cancer that involves surgery, radiation, and chemotherapy. The goal is to see if this new method is safe and effective.
Eligible Conditions
- Glioma
- Brain
- Anaplastic Astrocytoma (AA)
- Neoplasms, Brain
- Anaplastic Oligo-astrocytoma (AOA)
- Malignant Neoplasms of Brain
- Glioblastoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: 2 years
2 years
Overall Survival (OS)
6 months
Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)
Progression Free Survival (PFS)
Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
1 Treatment Group
Intra-arterial Cetuximab with Re-Irradiation
1 of 1
Experimental Treatment
37 Total Participants · 1 Treatment Group
Primary Treatment: Intra-arterial Cetuximab · No Placebo Group · Phase 2
Intra-arterial Cetuximab with Re-IrradiationExperimental Group · 3 Interventions: Intra-arterial Mannitol, Intra-arterial Cetuximab, Hypofractionated re-irradiation · Intervention Types: Drug, Drug, Radiation
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Who is running the clinical trial?
Northwell HealthLead Sponsor
420 Previous Clinical Trials
490,660 Total Patients Enrolled
5 Trials studying Glioma
512 Patients Enrolled for Glioma
John Boockvar, MD3.916 ReviewsPrincipal Investigator - Northwell Health
Northwell Health
11 Previous Clinical Trials
738 Total Patients Enrolled
2 Trials studying Glioma
442 Patients Enrolled for Glioma
5Patient Review
This neurosurgeon is nothing short of a hero. They are a miracle worker.
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥ three months.
You are a male or female patient of at least 18 years of age.
Patients must have at least one confirmed and evaluable tumor site.
You have a confirmed tumor site.
You have a coagulation profile that is less than 1.5 times the upper limit of normal.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments